Leverkusen, Germany, November 22, 2013 – Bayer HealthCare and Onyx Pharmaceuticals, Inc., an Amgen subsidiary (Nasdaq: AMGN), today announced that the U.S. Food and Drug Administration (FDA) has approved the oral multi-kinase inhibitor Nexavar® (sorafenib) for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine (RAI) treatment. Nexavar was approved following a priority review by the FDA, a designation reserved for drugs that offer a significant improvement in treatment over existing options....